PRINCETON, NJ AND WALTHAM, MA (October 21, 2009):

BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they
have entered into an agreement which provides NKTT with access to BioWa’s patented
POTELLIGENT® Technology platform for the development of antibody-dependent cellular
cytotoxicity (ADCC) enhanced antibodies.

GENEVA, SWITZERLAND (September 1, 2009):

Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M™. The Selexis INTEGRAD2M™ platform enables the rapid isolation of production cell lines concomitant with the selection of lead compounds from libraries of protein variants expressed in Chinese Hamster Ovary (CHO) cells. Utilizing INTEGRA-D2M™, protein variant libraries of sizes larger than 103 can be screened to identify lead compounds in less than 9 weeks. The selected CHO-based protein variant expressing clone can then be used directly for cGMP manufacturing.

WALTHAM, MA (July 27, 2009):

NKT Therapeutics Broadens Scientific Advisory Board with Three New Appointments NEWTON, MA (June __, 2009): NKT Therapeutics, Inc., a privately held biotechnology company, today announced three new appointments to the company’s scientific advisory board (SAB). The additions include:

• Peter Cresswell, Ph.D., Professor of Immunobiology, Cell Biology and Dermatology at Yale University School of Medicine
• Peter A. Kiener, D. Phil., Executive Vice President, Research & Development at MedImmune.
• David Wofsy, M.D., Professor of Medicine and Microbiology/Immunology at the University of California, San Francisco